MiNK Therapeutics shared a post on LinkedIn:
“MiNK Therapeutics Reports Q3 2025 Results and Advances iNKT Platform Toward Pivotal Development.
This quarter, MiNK continued to deliver strong scientific and operational momentum reporting durable clinical responses with agenT-797 in solid tumors, launching an NIH– and philanthropy-funded trial in GvHD, and strengthening our leadership to accelerate late-stage programs in oncology, inflammation, and transplantation.
With these achievements and preparations for Phase 2 pivotal-enabling studies, MiNK is advancing a next-generation class of off-the-shelf iNKT therapies designed to restore immune balance and address diseases where conventional approaches have failed.
More posts about MiNK.